Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CASR | P41180 | 13/20 | 1.00 |
| ▸ | NPC1 | O15118 | 3/20 | 0.48 |
| ▸ | RAB9A | P51151 | 3/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.48 |
| ▸ | LMNA | P02545 | 1/20 | 0.48 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.48 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.48 |
| ▸ | RELA | Q04206 | 1/20 | 0.48 |
| ▸ | MEN1 | O00255 | 2/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | HPGD | P15428 | 1/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 3/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.39 |
| ▸ | SCD | O00767 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29468186 | 1.00 | CASR (1.00) | CASRNPC1RAB9ASMN1; SMN2LMNA | |
| SCHEMBL28299855 | 0.79 | CASR (0.68) | CASRNPC1RAB9ASMN1; SMN2LMNA | |
| SCHEMBL7544923 | 0.74 | CASR (0.64) | CASRLMNAALDH1A1HPGD | |
| SCHEMBL18546040 | 0.72 | CASR (0.53) | CASRNPC1RAB9ASMN1; SMN2LMNA | |
| SCHEMBL227210 | 0.70 | CASR (0.58) | CASRNPC1RAB9ASMN1; SMN2LMNA | |
| SCHEMBL108180 | 0.70 | CASR (0.58) | CASRNPC1RAB9ASMN1; SMN2LMNA | |
| SCHEMBL30731326 | 0.70 | RAB9A (0.54) | CASRNPC1RAB9ASMN1; SMN2LMNA | |
| SCHEMBL27286220 | 0.69 | CASR (0.57) | CASRNPC1RAB9ASMN1; SMN2MEN1 | |
| SCHEMBL30731332 | 0.69 | CASR (0.57) | CASRNPC1RAB9ASMN1; SMN2LMNA | |
| SCHEMBL29226448 | 0.69 | CASR (0.71) | CASRNPC1RAB9ASMN1; SMN2NFKB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11730769-B2 | Compositions and methods for Williams Syndrome (WS) therapy | CHILDREN'S MEDICAL CENTER CORPORATION (US) | 2023-08-22 | — | — | US | disclosed |
| US-11730769-B2 | Compositions and methods for Williams Syndrome (WS) therapy | CHILDREN'S MEDICAL CENTER CORPORATION (US) | 2023-08-22 | — | — | US | disclosed |
| US-20200316132-A1 | COMPOSITIONS AND METHODS FOR WILLIAMS SYNDROME (WS) THERAPY | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2020-10-08 | — | — | US | disclosed |
| US-20190274334-A1 | COMPOUNDS THAT MODULATE CALCIUM-SENSING RECEPTOR ACTIVITY FOR MODULATING KOKUMI TASTE AND PET FOOD PRODUCTS CONTAINING THE SAME | MARS, INCORPORATED (US) | 2019-09-12 | — | — | US | disclosed |
| US-20190274334-A1 | COMPOUNDS THAT MODULATE CALCIUM-SENSING RECEPTOR ACTIVITY FOR MODULATING KOKUMI TASTE AND PET FOOD PRODUCTS CONTAINING THE SAME | MARS, INCORPORATED (US) | 2019-09-12 | — | — | US | disclosed |
| EP-3442352-A1 | COMPOUNDS THAT MODULATE CALCIUM-SENSING RECEPTOR ACTIVITY FOR MODULATING KOKUMI TASTE AND PET FOOD PRODUCTS CONTAINING THE SAME | Mars, Incorporated (US) | 2019-02-20 | — | — | EP | disclosed |
| WO-2017181062-A1 | COMPOUNDS THAT MODULATE CALCIUM-SENSING RECEPTOR ACTIVITY FOR MODULATING KOKUMI TASTE AND PET FOOD PRODUCTS CONTAINING THE SAME | MARS, INCORPORATED (US) | 2017-10-19 | — | — | WO | disclosed |
| WO-2017181062-A1 | COMPOUNDS THAT MODULATE CALCIUM-SENSING RECEPTOR ACTIVITY FOR MODULATING KOKUMI TASTE AND PET FOOD PRODUCTS CONTAINING THE SAME | MARS, INCORPORATED (US) | 2017-10-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11730769-B2 | Compositions and methods for Williams Syndrome (WS) therapy | MAG, PMP22, WDR77 | CASR 3981/4885NPC1 633/4885RAB9A 2005/4885 |
| US-20200316132-A1 | COMPOSITIONS AND METHODS FOR WILLIAMS SYNDROME (WS) THERAPY | MAG, PMP22, WDR77 | CASR 3981/4885NPC1 633/4885RAB9A 2005/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.